Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kynos Therapeutics

Request full access

First-in-class KMO inhibitors for treating inflammatory diseases

Edinburgh, United KingdomFounded 2020Biotech & Life Sciences

About Kynos Therapeutics

Kynos Therapeutics is a clinical-stage biopharmaceutical company that develops novel treatments for inflammatory diseases. The company was founded in 2020 as a spin-out from the University of Edinburgh by Professors Damian Mole and Scott Webster, based on over a decade of research into kynurenine 3-monooxygenase (KMO) biology. Jonathan Savidge has served as CEO since 2022.

The company focuses on developing inhibitors for the enzyme KMO, which plays a key role in regulating inflammation, immunity, and metabolism. By inhibiting KMO, the company's therapies aim to prevent excess tissue damage and immune system dysregulation. Its lead drug candidate, KNS366, is a highly selective, first-in-class KMO inhibitor. In a Phase I clinical trial, KNS366 was found to be safe, well-tolerated, and demonstrated potent inhibition of the KMO enzyme. The company's therapeutic pipeline targets critical illness post-surgery, conditions driven by inflammation, and certain cancers.

Kynos Therapeutics emerged from stealth in April 2022 with £9 million in financing, which included a £6.5 million equity round led by Epidarex Capital with participation from IP Group and Scottish Enterprise, and a £2.5 million grant from Innovate UK. The company was acquired by Dr. Falk Pharma GmbH in October 2024 and is now part of the Falk Group. Dr. Falk Pharma will continue the clinical development of KNS366, initially focusing on its application for acute pancreatitis, and integrating it into its own R&D pipeline for rare digestive and metabolic diseases.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2020
Headquarters
Edinburgh, United Kingdom
Employees
1
Open positions
None listed
Dealroom signal
54.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, uk is8 life sciences, UKSU2010, Spinout, UKSU, Hard Tech, science-based, DT and LS, Biotech and Pharma, Biotechnology
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Oct 2024 $0 — Dr. Falk Pharma ↗
GRANT✓Other financing Apr 2022 $3.3M — Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Kynos Therapeutics website traffic

Latest recorded traffic for Kynos Therapeutics is 390 monthly website visits, up 1200% over the last three months. Kynos Therapeutics's team declined 66.7% over the past year.

Latest monthly visits390 3-month web change+1200% 1-year team growth-66.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kynos Therapeutics in the Edinburgh ecosystem

Live from Dealroom

The Kynos Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Epidarex Capital
  • Scottish Enterprise Growth Investments
  • IP Group

Other known investors2 additional known investors

  • Dr. Falk Pharma
  • University of Edinburgh
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇬🇧 United Kingdom · Edinburgh HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kynos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kynos Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.